Document:

EX-4.4

 Exhibit 4.4 

NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUED UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO THE PROVISIONS OF SECTION 11 BELOW, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY
COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF THIS
WARRANT. 
 WARRANT AGREEMENT 

To Purchase Shares of the Preferred Stock of 

TRANSMEDICS, INC. 
 Dated as of
August 4, 2016 (the “Effective Date”) 
 WHEREAS, TransMedics, Inc., a Delaware corporation (the
“Company”), has entered into a Loan and Security Agreement dated September 11,2015 (as amended from time to time, the “Loan Agreement”) with Hercules Capital, Inc., a Maryland corporation f/k/a Hercules
Technology Growth Capital, Inc. (the “Warrantholder”): 
 WHEREAS, the Company desires to grant to Warrantholder, in
consideration for, among other things, the financial accommodations provided for in a certain amendment of even date herewith to the Loan Agreement, the right to purchase shares of its Preferred Stock (as defined below) pursuant to this Warrant
Agreement (the “Warrant” or the “Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder
executing and delivering the Loan Agreement and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

(a)      For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled,
upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to such number of fully paid and non-assessable shares of the Preferred Stock (as defined
below) as determined pursuant to Section 1(b) below, at a purchase price per share equal to the Exercise Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used
herein, the following terms shall have the following meanings: 
 “Act” means the Securities Act of 1933, as amended. 

 “Charter” means the Company’s Certificate of Incorporation as amended
and/or restated and in effect from time to time. 
 “Common Stock” means the Company’s common stock, $0.0001 par value
per share. 
 “Exercise Price” means the purchase price per share of Preferred Stock hereunder, and shall be the Series F
Price; provided, that upon consummation of the Next Equity Round, if any, if the Next Equity Round Price shall be lower than the Series F Price in effect as of immediately prior to such consummation, then the “Exercise Price” shall
mean the Next Equity Round Price, subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which registration statement has been declared effective by the Securities and Exchange Commission (“SEC”); 

“Merger Event” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive
license, or other disposition of all or substantially all of the assets of the Company, (ii) the merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change
the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s
(or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or
successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by the stockholders of the Company of shares representing at
least a majority of the Company’s then-total outstanding combined voting power. 
 “Next Equity Round” means the first
sale and issuance by the Company after the Effective Date hereof, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more investors for cash for
financing purposes resulting in gross cash proceeds to the Company of at least $10,000,000. 
 “Next Equity Round Price”
means the lowest effective price per share paid by investors for shares of the Next Equity Round Series in the Next Equity Round. 

“Next Equity Round Series” means the class and series of convertible preferred stock or other senior equity security sold and
issued by the Company in the Next Equity Round. 
 “Preferred Stock” means the Series F Preferred Stock, $0.0001 par value
per share, of the Company and any other stock into or for which such Series F Preferred Stock may be converted or exchanged; provided, that upon the consummation of the Next Equity Round, if any, if the Next Equity Round Price shall be lower
than the Series F Price in 

  
 2 

 
effect as of immediately prior to such consummation, then “Preferred Stock” shall mean the Next Equity Round Series and any other stock into or for which such Next Equity Round Series
may be converted or exchanged; provided, further, that subject to Section 8(f) below, upon the conversion into Common Stock of all (but not less than all) of the outstanding shares of such Preferred Stock (including, without
limitation, in connection with the Initial Public Offering), (i) this Warrant shall be exercisable for such number of shares of Common Stock as is equal to the number of shares of Common Stock that each share of Preferred Stock was converted into,
multiplied by the number of shares of Preferred Stock subject to this Warrant immediately prior to such conversion (subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant), (ii) the Purchase
Price shall be the Purchase Price in effect immediately prior to such conversion divided by the number of shares of Common Stock into which each share of Preferred Stock was converted (subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant), and (iii) all references to this Warrant to “Preferred Stock” shall thereafter be deemed to refer to “Common Stock.” 

“Purchase Price” means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the
relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Warrant pursuant to such exercise. 

“Rights Agreement” means that certain Eighth Amended and Restated Investor Rights Agreement dated as of June 14, 2013 by
and among the Company and certain holders of the Company’s capital stock, as amended on May 29,2015 and as it may be further amended or restated from time to time. 

“Series F Price” means $4.99, as may be adjusted from time to time in accordance with the provisions of this Warrant. 

(b)      Number of Shares. This Warrant shall be exercisable for such number of shares of Preferred Stock
as shall equal (i) $170,000, divided by (ii) the Exercise Price in effect from time to time, subject to adjustment from time to time in accordance with the provisions of this Warrant. 

 

	 	SECTION	 2. TERM OF THE WARRANT. 

Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein shall commence
on the Effective Date and shall be exercisable for a period ending upon the later to occur of (i) the seventh (7th) anniversary of the Effective Date, and (ii) if the Initial Public
Offering shall be consummated on or before the seventh (7th) anniversary of the Effective Date, the date that is five (5) years following the effective date of the Company’s registration
statement in connection with the Initial Public Offering. 
  

	 	SECTION	 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a)      Exercise. The purchase rights set forth in this Warrant are exercisable by the Warrantholder, in
whole or in part, at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of 

  
 3 

 
exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”) duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment
of the Purchase Price in accordance with the terms set forth below, and in no event later than ten (10) days (three (3) days, if the Company’s securities are then publicly traded) thereafter, the Company shall issue to the
Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the
number of shares which remain subject to future purchases, if any. 
 The Purchase Price may be paid at the Warrantholder’s election
either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Preferred Stock to be exercised under this Warrant and, if applicable, a new warrant of like tenor representing the remaining number of
shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 

 

					
		  	 X = Y(A-B)

A

			
	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Warrant (including the number of shares to be cancelled in payment of the Purchase Price).
			
		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, the fair market value of Preferred Stock shall mean with respect to
each share of Preferred Stock: 
 (i)      if the exercise is in connection with an Initial
Public Offering, and if the Company’s Registration Statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to
Public” of the Common Stock specified in the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii)      if the exercise is after, and not in connection with an Initial Public Offering, and:

 (A)      if the Common Stock is traded on a securities exchange, the fair market value
shall be deemed to be the product of (x) the average of the closing prices over a five (5) day period ending three days before the day the then-current fair market value of the securities is being determined and (y) the number of

  
 4 

 
shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; or 

(B)      if the Common Stock is traded over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day
period ending three days before the day the then-current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise;

 (iii)      if at any time the Common Stock is not listed on any securities exchange or
quoted in the over-the-counter market, the fair market value of Preferred Stock shall be the product of (x) the fair market value of Common Stock, as determined in
good faith by its Board of Directors and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise, provided that in the event that the exercise is in connection with a
Merger Event, the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Company’s Preferred Stock on a common equivalent basis pursuant to such Merger Event. 

Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue a new warrant representing the remaining number of
shares purchasable hereunder. All other terms and conditions of such new Warrant shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 

(b)      Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all
Preferred Stock subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 3(a) (even if not
surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Warrant or
any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by reason of such
automatic exercise. 
  

	 	SECTION	 4. RESERVATION OF SHARES. 

During the term of this Warrant, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred
Stock to provide for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the Preferred Stock
issuable hereunder. 

  
 5 

	 	SECTION	 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional
shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
  

	 	SECTION	 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 

This Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder/stockholder of the Company prior to
the exercise of this Warrant. 
  

	 	SECTION	 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Warrant. Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(f) below. Warrantholder may change such address by giving written notice of such changed address to the Company. 

 

	 	SECTION	 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 

(a)      Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event,
lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of preferred stock or other securities or property (collectively, “Reference
Property”) that the Warrantholder would have received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good
faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this
Agreement (including adjustments of the Exercise Price and the number and nature of the security issuable on exercise hereof, and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as possible,
to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting
the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement; provided, that the foregoing assumption requirement shall not apply if the
consideration to be paid for or in respect of the outstanding shares of Preferred Stock in such Merger Event consists solely of cash and/or readily marketable securities. In connection with a Merger Event and upon Warrantholder’s written
election to the Company, delivered not later than the later to occur of (i) five (5) days prior to the anticipated closing date thereof set forth in the Company’s written notice to the Warrantholder of such Merger Event pursuant to
Section 8(g) below, or (ii) ten (10) days after the Warrantholder’s actual receipt of such Company notice, shall cause this Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder had
chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Agreement without actually 

  
 6 

 
exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this Section 8(a) shall similarly apply to successive Merger Events. 

(b)      Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any time
shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of securities of any other class or
classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this
Warrant immediately prior to such combination, reclassification, exchange, subdivision or other change. 

(c)      Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its
Preferred Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Preferred Stock issuable upon exercise of this Warrant shall be proportionately increased, or (ii) in the
case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Preferred Stock issuable upon the exercise of this Warrant shall be proportionately decreased. 

(d)      Stock Dividends. If the Company at any time while this Warrant is outstanding and unexpired
shall: 
 (i)      pay a dividend with respect to the Preferred Stock payable in Preferred
Stock, then the Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to
such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total
number of shares of Preferred Stock outstanding immediately after such dividend or distribution; or 

(ii)      make any other distribution with respect to Preferred Stock (or stock into which the
Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise of
this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the stockholders of
the Company entitled to receive such distribution. 
 (e)      Antidilution Rights. Antidilution rights
applicable to the Preferred Stock purchasable hereunder are as set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly provide the Warrantholder with any restatement,
amendment, modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the date hereof unless such amendment,
modification or waiver applies to all then-outstanding shares of Preferred Stock. For the avoidance of doubt, there shall be no 

  
 7 

 
duplicate anti-dilution adjustment pursuant to this Section 8(e), the forgoing Section 8(d) and the Charter. 

(f)      “Pay to Play” Rights. In the event that any “pay to play” terms or
conditions (i.e. terms or conditions that require a holder of the Preferred Stock to purchase securities in a future round of equity financing or else lose the benefit of anti-dilution protections or other rights applicable to shares of Preferred
Stock or have such shares of Preferred Stock automatically convert into Common Stock or another class or series of capital stock) in the Charter are triggered in connection with any Equity Round (a “Trigger Event”), then, in each
such event, the purchase rights under this Agreement shall automatically adjust to provide the Warrantholder, upon the later exercise hereof, with the same securities and/or rights that the Warrantholder would have received had the Warrantholder
(x) exercised this Warrant prior to such Trigger Event, and (y) participated in the applicable equity financing in an amount sufficient to be deemed to have fully participated for purposes of such “pay to play” provision. For
avoidance of doubt, the foregoing provisions of this Section 8(f) shall not apply to any shares of Preferred Stock issued upon exercise of this Warrant and outstanding on and as of the date of any such Trigger Event. 

(g)      Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon
outstanding shares of the Preferred Stock, whether in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of outstanding shares of the Preferred Stock any additional shares of stock
of any class or series or other rights (other than pursuant to contractual pre-emptive rights); (iii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (v) the Company
shall sell, lease, license or otherwise transfer all or substantially all of its assets; or (vi) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall
send to the Warrantholder: (A) at least fifteen (15) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying the
date on which the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, license or
other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least fifteen (15) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of
Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company
shall give the Warrantholder at least fifteen (15) days1 written notice prior to the filing of the registration statement in connection therewith. 

Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is
required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to
purchase hereunder after giving effect to such adjustment, and shall be given in the manner set forth in Section 12(f). 

(h)      Timely Notice. Failure to timely provide such notice required by Section 8(g) above shall
entitle Warrantholder to retain the benefit of the applicable notice period 

  
 8 

 
notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder. 
  

	 	SECTION	 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

The Company makes the following representations and warranties to the Warrantholder as of the Effective Date 

(a)      Reservation of Preferred Stock. The Series F Preferred Stock issuable upon exercise of the
Warrantholder’s rights has been duly and validly reserved and, when issued in accordance with the provisions of this Warrant, will be validly issued, fully paid and non-assessable, and will be free of any
taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Warrant may be subject to restrictions on transfer hereunder and under state and/or federal securities laws. The
Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon exercise of this Warrant shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any
tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

(b)      Due Authority. The execution and delivery by the Company of this Warrant and the performance of
all obligations of the Company hereunder, including the grant to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which such Preferred Stock may be converted, have been duly authorized by all necessary
corporate action on the part of the Company. The execution and delivery of this Warrant by the Company: (i) do not violate the Charter or current bylaws; (ii) do not contravene any law or governmental rule, regulation or order applicable
to it; and (iii) do not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Warrant constitutes a valid and binding agreement of
the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights of creditors
generally and by equitable principles, including those limiting the availability of specific performance, injunctive relief and other equitable remedies and those providing for equitable defenses. 

(c)      Consents and Approvals. Subject to the accuracy of the representations of the Warrantholder in
Section 10, no consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and
performance by the Company of its obligations under this Warrant, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time
required thereby. 

  
 9 

 (d)      Issued Securities. All issued and outstanding
shares of Common Stock, preferred stock and other securities of the Company have been duly authorized and validly issued, and all outstanding shares of capital stock of the Company are fully paid and
non-assessable. All outstanding shares of Common Stock, preferred stock and any other securities were issued in compliance in all material respects with all federal and state securities laws. In addition, as
of the date immediately preceding the date of this Warrant: 
 (i)      The authorized capital
of the Company consists of (A) 60,000,000 shares of Common Stock, of which 4,449,990 shares are issued and outstanding, and (B) 50,776,054 shares of preferred stock of all series, of which (1) 13,332 shares have been designated as Series A-l Preferred Stock, of which all shares are issued and outstanding and each such share is convertible into approximately 0.25826 share of Common Stock; (2) 3,771,020 shares have been designated as Series B
Preferred Stock, of which 3,624,650 shares are issued and outstanding and each such share is convertible into approximately 0.27626 share of Common Stock; (3) 2,560,245 shares have been designated as Series
B-l Preferred Stock, of which all shares are issued and outstanding and each such share is convertible into approximately 0.27626 share of Common Stock; (4) 6,198,057 shares have been designated as Series C
Preferred Stock, of which all shares are issued and outstanding and each such share is convertible into one (1) share of Common Stock; (5) 14,740,000 shares have been designated as Series D Preferred Stock, of which 14,565,000 shares are issued
and outstanding and each such share is convertible into one (1) share of Common Stock; (6) 6,562,232 shares have been designated as Series E Preferred Stock, of which all shares are issued and outstanding and each such share is convertible into
one (1) share of Common Stock; (7) 16,931,168 shares have been designated as Series F Preferred Stock, of which 16,880,624 shares are issued and outstanding and each such share is convertible into one (1) share of Common Stock. 

(ii)      The Company has reserved 6,672,151 shares of Common Stock in the aggregate for
issuance under its 2014 Stock Incentive Plan. Options to purchase 4,624,455 shares are outstanding under the Company’s 2004 Stock Incentive Plan and 2014 Stock Incentive Plan. No additional shares are issuable under the Company’s 2004
Stock Incentive Plan. The Company has outstanding warrants to purchase an aggregate of 146,370 shares of its Series B Preferred Stock, warrants to purchase an aggregate of 175,000 shares of its Series D Preferred Stock and warrants to purchase an
aggregate of 16,476 shares of its Series F Preferred Stock. The Company also has one option outstanding to purchase 30,000 shares of its Common Stock which was issued outside the 2014 Stock Incentive Plan. Other than as described in these clauses
(i) and (ii), there are no other options, warrants, conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the
Company (except for the Warrantholder’s rights pursuant to Section 8 of the Loan Agreement and pursuant to this Warrant). 

(e)      Other Commitments to Register Securities. Except as set forth in the Rights Agreement, the
Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 

  
 10 

 (f)      Exempt Transaction. Subject to the accuracy of
the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of this Warrant, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt
from (i) the registration requirements of Section 5 of the Act, and (ii) the qualification requirements of the applicable state securities laws. 

(g)      Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon
the exercise of this Warrant, or the Common Stock into which it is convertible, after the Initial Public Offering in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall
furnish to the Warrantholder, within ten (10) days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from
time to time. 
 (h)      Information Rights. During the term of this Warrant, Warrantholder shall be
entitled to the information rights contain in Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Warrant by this reference as though fully set forth herein, provided,
however, that the Company shall not be required to deliver a Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid. The Company shall also supply to the
Warrantholder from time to time upon its request such documentation as is reasonably necessary to permit the Warrantholder to evaluate whether to exercise (in cash or a net issuance basis) this Warrant, including without limitation, (i) any
merger/purchase/asset sale agreement and related documents and estimated payout allocations to each of the respective shareholders, warrant and option holders in connection with a Merger Event, (ii) the most recent capitalization tables,
(iii) such information and materials as are reasonably necessary to support any determination of fair market value of the Common Stock by the Company’s board of directors pursuant to Section 3(a)(iii)(x) above, and (iv) the most
recent Charter. 
  

	 	SECTION	 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder, which
representations and covenants are made on the Effective Date and upon each exercise of this Warrant (including any automatic exercise): 

(a)      Investment Purpose. The right to acquire Preferred Stock, the Preferred Stock issuable upon
exercise of the Warrantholder’s rights contained herein and the Common Stock issuable upon conversion of the Preferred Stock will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the
Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 

(b)      Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon
exercise of this Warrant and the Common Stock issuable upon conversion of the Preferred Stock is not registered under the Act or qualified under applicable state securities laws on the 

  
 11 

 
ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such
exemption is predicated on the representations set forth in this Section 10. 
 (c)      Financial
Risk. The Warrantholder has sufficient knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment in the
Company. The Warrantholder has made such inquiry concerning the Company and its business and personnel as it has deemed appropriate. 

(d)      Risk of No Registration. The Warrantholder understands that if the Company does not register
shares of its capital stock with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering
the shares of its capital stock under the Act is not in effect when the Warrantholder desires to sell (i) this Warrant, (ii) the Preferred Stock issuable upon exercise of this Warrant or (iii) the Common Stock issuable upon conversion
of the Preferred Stock issuable upon exercise of this Warrant, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) this Warrant or (B) Preferred Stock issued or
issuable hereunder, or the Common Stock issuable upon conversion thereof, which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 

(e)      Accredited Investor. Warrantholder is an “accredited investor” within the meaning of
Rule 501 of Regulation D, as presently in effect under the Act. 
 (f)      Market “Stand-off’ Agreement. The Warrantholder agrees, if requested by the Company and the managing underwriter of the Initial Public Offering, (a) not to (i) offer, pledge, announce the intention
to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, this Warrant, the
Preferred Stock or other shares of capital stock issuable upon exercise of this Warrant (or the conversion of any such shares), or any other securities of the Company or (ii) enter into any swap or other arrangement that transfers, in whole or
in part, any of the economic consequences of ownership of this Warrant, the Preferred Stock or other shares of capital stock issuable upon exercise of this Warrant (or the conversion of any such shares), or any other securities of the Company
(excluding securities acquired in the Initial Public Offering or in the public market after the Initial Public Offering), whether any transaction described in clause (i) or (ii) is to be settled by delivery of securities, in cash or otherwise,
during the period beginning on the date of the filing of the registration statement relating to the Initial Public Offering with the SEC and ending 180 days after the date of the final prospectus relating to the Initial Public Offering (plus up to
an additional 34 days to the extent requested by the managing underwriters for such offering in order to address Rule 2711(f) of the National Association of Securities Dealers, Inc. or any similar successor provision) and (b) to execute any
agreement reflecting clause (a) above as may be requested by the Company or the managing underwriters of the Initial Public Offering; provided, that all directors and officers of the Company, and all holders of one percent (1%) or more
of the Company’s Common Stock (calculated on a fully-diluted, as-exercised, as-converted basis) enter into similar agreements with the Company and/or managing
underwriter; provided, 

  
 12 

 
further, that if the Company or managing underwriter releases any such director, officer or stockholder from his or its obligations under such agreement prior to the expiration thereof,
the Warrantholder shall thereupon automatically be released from its obligations under this Section 10(f) and its agreement with the Company and/or managing underwriter to the same extent. In order to enforce the foregoing, the Company may
impose stop-transfer instructions with respect to such securities until the end of such lock-up period and may cause such securities to bear a legend setting forth such restriction until the end of such lock-up period. The underwriters for the Initial Public Offering are intended third party beneficiaries of this Section 10(f) and shall have the right, power and authority to enforce the provisions hereof as
though they were parties hereto. 
  

	 	SECTION	 11.             TRANSFERS.

 Subject to compliance with applicable federal and state securities laws and with the provisions of this
Section 11, this Warrant and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Warrant properly endorsed. Each taker and holder of this Warrant, by
taking or holding the same, consents and agrees that the holder hereof, when this Warrant shall have been properly endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with
this Warrant as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Warrant. The transfer of this Warrant shall be recorded on the books of the Company upon receipt by the Company of a
notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer.
Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Neither this Warrant nor the shares of capital stock issuable upon exercise of this Warrant shall be sold or
transferred unless either (i) they first shall have been registered under the Act, or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale
or transfer is exempt from the registration requirements of the Act; provided, that the Company shall not require a legal opinion in connection with any transfer by Warrantholder of this Warrant and/or any shares of Preferred Stock issued
upon exercise hereof to an Affiliate of Warrantholder, provided that such transferee (i) is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect, and
(ii) agrees in writing with the Company to be bound by all of the obligations of the Warrantholder hereunder; provided, further, that following the consummation of the Initial Public Offering, the Company at its sole expense shall
cause its legal counsel to provide any such opinion required or requested by the Company or its transfer agent. At all times prior to the Initial Public Offering, the Warrantholder shall not, without the prior written consent of the Company,
(x) transfer this Warrant or any shares of Preferred Stock issued upon any exercise hereof to a person or entity that directly competes with the Company, except in connection with a Merger Event where the acquiring or surviving person or entity
is such a direct competitor, and (y) transfer this Warrant to any non-Affiliate except in whole. As used herein, an “Affiliate” of the Warrantholder means any person or entity directly or
indirectly controlling, controlled by or under common control with the Warrantholder. Each certificate representing shares of capital stock issuable upon exercise of this Warrant shall bear a legend substantially in the following form: 

  
 13 

 “The securities represented by this certificate have not been registered under the
Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or, subject to Section 11 of that certain Warrant Agreement dated
July ___, 2016 between the Company and Hercules Capital, Inc., an opinion of counsel satisfactory to the Company is obtained to the effect that such registration is not required.” 

 

	 	SECTION	 12.             MISCELLANEOUS.

 (a)      Effective Date. The provisions of this Warrant shall be construed and
shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b)      Remedies. In the event of any default hereunder, the
non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or
an action for specific performance for any default where the non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party expressly agrees that
it shall not oppose an application by the other party or any other person entitled to the benefit of this Warrant requiring specific performance of any or all provisions hereof or enjoining the other party from continuing to commit any such breach
of this Warrant. 
 (c)      No Impairment of Rights. The Company will not, by amendment of its Charter
or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

(d)      Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and
the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Warrant. For the purposes of this Section 12(d), reasonable
attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency
proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 

(e)      Severability. In the event any one or more of the provisions of this Warrant shall for any
reason be held invalid, illegal or unenforceable, the remaining provisions of this Warrant shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision,
which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 14 

 (f)      Notices. Except as otherwise provided herein,
any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Warrant or with respect to the subject matter hereof shall be in writing, and shall be
deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the
recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or
overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 

If to Warrantholder: 

HERCULES CAPITAL, INC. 

Legal Department 

Attention: Chief Legal Officer and Bryan Jadot 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 

Facsimile: 650-473-9194 

Telephone: 650-289-3060 

If to the Company: 

TransMedics, Inc. 

Attention: Chief Financial Officer 

200 Minuteman Road Suite 302 

Andover, MA 01810 

Facsimile: 978-685-9562 

Telephone: 978-552-0925 

With a copy to: 

WilmerHale 

60 State Street 

Boston, MA 02109 

Attn : Rosemary G. Reilly, Esq. 

Facsimile: 617-526-5000 

Telephone: 617-526-6000 

or to such other address as each party may designate for itself by like notice. 

(g)      Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding
of the parties hereto in respect of the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject
matter hereof (including Lender’s proposal letter dated July 24, 2015). None of the terms of this Warrant may be amended except by an instrument executed by each of the parties hereto. 

  
 15 

 (h)      Headings. The various headings in this Warrant
are inserted for convenience only and shall not affect the meaning or interpretation of this Warrant or any provisions hereof. 

(i)      Advice of Counsel. Each of the parties represents to each other party hereto that it has
discussed (or had an opportunity to discuss) with its counsel this Warrant and, specifically, the provisions of Sections 12(m), 12(n), 12(o), 12(p) and 12(q). 

(j)      No Strict Construction. The parties hereto have participated jointly in the negotiation and
drafting of this Warrant. In the event an ambiguity or question of intent or interpretation arises, this Warrant shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provisions of this Warrant. 
 (k)      No Waiver. No omission or
delay by either party at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the other party at any time designated, shall be a waiver of any such right or remedy
to which such party is entitled, nor shall it in any way affect the right of such party to enforce such provisions thereafter. 

(l)      Survival. All agreements, representations and warranties contained in this Warrant or in any
document delivered pursuant hereto shall be for the benefit of Warrantholder or the Company, as the case may be, and shall survive the execution and delivery of this Warrant and the expiration or other termination of this Warrant. 

(m)      Governing Law. This Agreement shall be governed by, and construed and enforced in accordance
with, (i) to the extent applicable, the Delaware General Corporation Law, and (ii) otherwise, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 (n)      Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related
to this Warrant shall be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Warrant, each party hereto generally and unconditionally: (a) consents to personal
jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the
aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Warrant. Service of process on any party hereto in any action arising out of or relating to this Warrant shall be effective if
given in accordance with the requirements for notice set forth in Section 12(f), and shall be deemed effective and received as set forth in Section 12(f). Nothing herein shall affect the right to serve process in any other manner permitted
by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

(o)      Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial
transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a
judge applying such 

  
 16 

 
applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR
ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons
other than the Company and the Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or
legal relief of any kind, arising out of this Warrant. 
 (p)      Arbitration. If the Mutual Waiver of
Jury Trial set forth in Section 12(o) is ineffective or unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the “Rules”), such
arbitration to occur before one arbitrator, which arbitrator shall be a retired California state judge or a retired Federal court judge. Such proceeding shall be conducted in San Francisco County, California, with California rules of evidence and
discovery applicable to such arbitration. The decision of the arbitrator shall be binding on the parties, and shall be final and non-appealable to the maximum extent permitted by law. Any judgement rendered by
the arbitrator may be entered in a court of competent jurisdiction and enforced by the prevailing party as a final judgment of such court. 

(q)      Pre-arbitration Relief. In the event Claims are to be
resolved by arbitration, either party may seek from a court of competent jurisdiction identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent
permitted by law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration. 

(r)      Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be
executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

(s)      Specific Performance. The parties hereto hereby declare that it is impossible to measure in
money the damages which will accrue to a party by reason of the other party’s failure to perform any of its respective obligations under this Warrant and agree that the terms of this Warrant shall be specifically enforceable by each party. If a
party hereto institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party has an adequate remedy at law,
and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 [Remainder of Page
Intentionally Left Blank] 

  
 17 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
its officers thereunto duly authorized as of the Effective Date 
 COMPANY: TRANSMEDICS, INC. 

 

			
		
	By:	 	/s/ Waleed Hassanein

 
			
		
	Name:	 	Waleed Hassanein

 
			
		
	Title:	 	CEO & President and Secretary

 WARRANTHOLDER: HERCULES CAPITAL, INC. 

 

			
		
	By:	 	/s/ Jennifer Choe

 
			
		
	Name:	 	Jennifer Choe

 
			
		
	Title:	 	Assistant General Counsel

  
 18 

 EXHIBIT I 

NOTICE OF EXERCISE 
 To:
[______________________________] 
  

	(1)	 The undersigned Warrantholder hereby elects to purchase [____] shares Of the Series [__] Preferred Stock of
[______________________], pursuant to the terms of the Agreement dated the [____] day of [_________, ____] (the “Agreement”) between [______________________] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the
Purchase price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

 

	(2)	 Please issue a certificate or certificates representing said shares of Series [__] Preferred Stock in the name
of the undersigned or in such other name as is specified below. 

  

							
		 		 	 (Name)
  

		 		 	(Address)
			
	WARRANTHOLDER:	 		 	HERCULES CAPITAL, INC.
				
		 		 	By:	 	 
				
		 		 	Title:	 	 

  
 19 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[___________________________], hereby acknowledge receipt of the “Notice of Exercise” from Hercules Capital, Inc., to purchase [___] shares of the Series [_____] Preferred Stock of [________________], pursuant to the terms of the
Agreement, and further acknowledges that [_______] shares remain subject to purchase under the terms of the Agreement. 
 COMPANY:
[________________] 
 By: _________________________ 

Title: _________________________ 

Date: _________________________ 

  
 20 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

 
 (Please Print) 

 

	
	whose address is ________________________________________________________________________________________

  
  

Dated: ______________________________________ 

Holder’s Signature: ____________________________ 

Holder’s Address: ______________________________ 

                          
              _____________________________________________ 
 Signature Guaranteed:
__________________________ 
 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without
alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 21EX-10.2

 Exhibit 10.2 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of [    ], 2019, by and between TransMedics
Group, Inc., a Massachusetts corporation (the “Company”), and [    ] (“Indemnitee”). 

RECITALS 
 WHEREAS,
although the Articles of Organization and Bylaws of the Company provide for indemnification of the officers and directors of the Company and Indemnitee may also be entitled to indemnification pursuant to the Massachusetts Business Corporation Act
(the “Act,” as further defined below), the Act expressly contemplates that contracts may be entered into between the Company and its directors and officers with respect to indemnification of such directors and officers; 

WHEREAS, Indemnitee’s continued service to the Company substantially benefits the Company; 

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that it is in the best interest of the Company
and that it is reasonably prudent and necessary for the Company to contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee to the fullest extent permitted by applicable law in order to induce Indemnitee to serve
or continue to serve the Company free from undue concern that Indemnitee will not be so indemnified or that any indemnification obligation will not be met; 

WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Articles of Organization and Bylaws, as
the case may be, of any Enterprise (as defined below), and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; 

WHEREAS, Indemnitee does not regard the protection available under the Company’s Articles of Organization, Bylaws, and insurance, or any
other Enterprise’s certificate of incorporation, bylaws, partnership agreement or other organizational document, as the case may be, and insurance, as adequate in the present circumstances, and may not be willing to serve as a director or
officer without adequate protection, and the Company desires Indemnitee to serve in such capacity, and Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company and certain other Enterprises
on the condition that Indemnitee be so indemnified; and 
 WHEREAS, if Indemnitee is a director or nominee to serve on the Board, Indemnitee
may have or may have in the future certain rights to indemnification and/or insurance provided by other entities and/or organizations which the Company, Indemnitee and such other entities and/or organizations intend to be secondary to the primary
obligation of the Company to indemnify Indemnitee as provided herein, with the Company’s acknowledgement and agreement to the foregoing being a material condition to Indemnitee’s willingness to serve on the Board. 

NOW, THEREFORE, in consideration of the promises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: 

 AGREEMENT 

1. Services to the Company and Certain Other Enterprises. Indemnitee will serve or continue to serve as a director
and/or officer of the Company or other Enterprises for so long as Indemnitee is duly elected or appointed or until Indemnitee tenders a resignation. 

2. Definitions. As used in this Agreement: 

(a) “Act” means Chapter 156D of the General Laws of the Commonwealth of Massachusetts, provided that if Chapter 156D is
amended, or other Massachusetts law is enacted in place of Chapter 156D, then Indemnitee shall be indemnified to the fullest extent permitted under Chapter 156D as so amended, or by such other Massachusetts law, as so enacted. 

(b) “Change of Control” means: 

(1) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), becomes the “Beneficial Owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting securities
(excluding for this purpose any such voting securities held by the Company, or any affiliate, parent or subsidiary of the Company or any employee benefit plan of the Company) pursuant to a transaction or a series of transactions which the Board does
not approve; 
 (2) a merger or consolidation of the Company, whether or not approved by the Board, which results in the holders of voting
securities of the Company outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) at least fifty percent (50%) of the combined
voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation; 

(3) the sale or disposition of all or substantially all of the Company’s assets (or consummation of any transaction having similar
effect) provided that the sale or disposition is of more than two-thirds (2/3) of the assets of the Company; or 
 (4) the date a majority
of members of the Board is replaced during any twelve- (12)-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election. 

In any case, a Change of Control under this Section 2(b) must also meet the requirements of a change in ownership or effective control,
or a sale of a substantial portion of the Company’s assets in accordance with Section 409A(a)(2)(A)(v) of the Internal Revenue Code of 1986, as amended, and the applicable provisions of Treasury Regulation § 1.409A-3. 

(c) “Corporate Status” describes the status of a person who is or was a director, officer, employee, agent or fiduciary of
the Company or of any other Enterprise. 
 (d) “Disinterested Director” means a director of the Company who is not and was
not a 

  
 2 

 
party to the Proceeding in respect of which indemnification is sought by Indemnitee. 

(e) “Enterprise” means (i) the Company, (ii) any other corporation, partnership, limited liability company, joint
venture, trust, employee benefit plan or other enterprise which is an affiliate or wholly or partially owned subsidiary of the Company and of which Indemnitee is or was serving as a director, trustee, general partner, managing member, officer,
employee, agent or fiduciary and (iii) any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company. 

(f) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(g) “Expenses” includes all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses shall include such fees and expenses, and costs incurred in connection with any appeal resulting from any
Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement by Indemnitee or
the amount of judgments or fines against Indemnitee. 
 (h) “Independent Counsel” means, at any time, any law firm, or a
member of a law firm, that (i) is experienced in matters of Massachusetts corporation law and (ii) is not, at such time, or has not been in the five years prior to such time, retained to represent: (1) the Company or Indemnitee in any
matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnities under similar indemnification agreements) or (2) any other party to the Proceeding giving rise to a
claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest
in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify
such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto and to be jointly and severally liable therefor. 

(i) “Proceeding” includes any threatened, pending or completed action, suit, arbitration, mediation, alternate dispute
resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether of a civil, criminal, administrative or
investigative nature, including without limitation any such proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was an officer or
director of the Company or by reason of the fact that Indemnitee is or was serving as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, in each case whether or not serving in such
capacity at the time any Expense, judgment, fine or amount paid in settlement is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. 

  
 3 

 3. Indemnity in Third-Party Proceedings. The Company shall be liable to indemnify
Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding, other than a Proceeding by or in the right of the Company
to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf
in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee (A) acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a
criminal Proceeding, had no reasonable cause to believe that Indemnitee’s conduct was unlawful, or (B) engaged in conduct for which Indemnitee shall not be liable under a provision of the Company’s Articles of Organization authorized
by Section 2.02(b)(4) of the Act or any successor provisions to the Act. Indemnitee’s conduct with respect to an employee benefit plan for a purpose Indemnitee reasonably believed to be in the interests of the participants in, and the
beneficiaries of, the plan is conduct that satisfies the requirement that Indemnitee’s conduct was at least not opposed to the best interests of the Company. 

4. Indemnity in Proceedings by or in the Right of the Company. The Company shall be liable to indemnify Indemnitee in accordance with
the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant (as a witness or otherwise) in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this
Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding (or any claim, issue or matter therein) if Indemnitee
(A) acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or (B) engaged in conduct for which Indemnitee shall not be liable under a provision of the Company’s
Articles of Organization authorized by Section 2.02(b)(4) of the Act or any successor provisions to the Act. Indemnitee’s conduct with respect to an employee benefit plan for a purpose Indemnitee reasonably believed to be in the interests
of the participants in, and the beneficiaries of, the plan is conduct that satisfies the requirement that Indemnitee’s conduct was at least not opposed to the best interests of the Company; provided, however that no
indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court of competent jurisdiction to be liable to the Company, unless and only
to the extent that any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to
indemnification. 
 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other
provisions of this Agreement, to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding, the Company shall be liable to indemnify Indemnitee against all Expenses actually and
reasonably incurred by the Indemnitee in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding,
the Company shall be liable to indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section
and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 

  
 4 

 6. Indemnification For Expenses of a Witness. Notwithstanding any other provision of
this Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, the Company shall be liable to indemnify Indemnitee against all Expenses actually and
reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. 
 7. Exclusions. Notwithstanding any
provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity payment in connection with any claim made against Indemnitee: 

(a) for which payment has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision,
except with respect to any excess beyond the amount actually received under any insurance policy or other indemnity provision; provided, that the foregoing shall not affect the rights of Indemnitee or the Fund Indemnitors (as defined below)
set forth in Section 13(c) below; 
 (b) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee
of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law; provided, however, that notwithstanding any limitation on the Company’s
obligation to provide indemnification set forth in this Section 7(b) or elsewhere, Indemnitee shall be entitled to receive advancement of Expenses hereunder with respect to any such claim unless and until a court having jurisdiction over the
claim shall have made a final judicial determination (as to which all rights of appeal therefrom have been exhausted or lapsed) that Indemnitee has violated said statute; or 

(c) in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee (other than to enforce this Agreement or other
indemnification rights), including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless the Proceeding was authorized by the Board. 

8. Advancement of Expenses; Defense of Claim. 

(a) Notwithstanding any provision of this Agreement to the contrary, the Company shall, before final, non-appealable disposition of a
Proceeding, be obligated to advance any and all Expenses incurred by Indemnitee in connection with any Proceeding within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time,
whether prior to or after final disposition of any Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of
Indemnitee to repay any Expenses advanced to the extent and only to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. Any advances (i) shall be unsecured and interest free,
(ii) shall be made without regard to Indemnitee’s ability to repay the advances and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement or otherwise and (iii) shall
include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Company will be entitled to
participate reasonably in the Proceeding at its own expense. 
 (b) Indemnitee shall repay to the Company any and all advances made to or
for the 

  
 5 

 
benefit of Indemnitee in a Proceeding if, following a final, non-appealable disposition of the Proceeding, (i) Indemnitee is not entitled to mandatory indemnification under Section 8.52
of the Act and (ii) it is ultimately determined under Sections 8.54 or 8.55 of the Act that Indemnitee has not meet the relevant standard of conduct described in Section 8.51 of the Act. 

9. Procedure for Notification and Requests for Advancement and Indemnification. 

(a) Notification. To obtain advancement of Expenses and/or indemnification under this Agreement, Indemnitee shall, not later than
sixty (60) days after receipt by Indemnitee of notice of the commencement of any Proceeding, except for Proceedings pending as of the date of this Agreement, submit to the Company written notification of the Proceeding; with regard to
Proceedings pending as of the date of this Agreement, Indemnitee shall submit to the Company written notification not later than thirty (30) days after the date of this Agreement. The omission to notify the Company will relieve the Company of
its advancement or indemnification obligations under this Agreement only to the extent the Company can establish that such omission to notify resulted in actual, material prejudice to it, and the omission to notify the Company will, in any event,
not relieve the Company from any liability which it may have to indemnify Indemnitee otherwise than under this Agreement. The Secretary of the Company shall, promptly upon receipt of notification from Indemnitee pursuant to this Section 9(a),
advise the Board in writing that Indemnitee has provided such notification. If, at the time of receipt of any such written request for advancement of Expenses, the Company has director and officer insurance policies in effect, the Company will
promptly notify the relevant insurers in accordance with the procedures and requirements of such policies. The Company shall thereafter keep such director and officer insurers informed of the status of the Proceeding or other claim, as appropriate
to secure coverage of Indemnitee for such claim. 
 (b) Expense Request. Subject to Section 8, to obtain advancement of
Expenses under this Agreement, Indemnitee shall submit to the Company (i) a written request therefor, together with such invoices or other supporting information as may be reasonably requested by the Company and reasonably available to
Indemnitee, and (ii) together with, or prior to the submission of, such invoices, (1) the written affirmation required under Section 8.53 of the Act of the Indemnitee’s good faith belief that the Indemnitee has met the relevant
standard of conduct described in Section 8.51 of the Act or that the proceeding involves conduct for which liability has been eliminated under a provision of the Company’s Articles of Organization as authorized by clause (4) of
subsection (b) of Section 2.02 of the Act and (2) the Indemnitee’s written undertaking required under Section 8.53 of the Act to repay any advanced funds as provided in Section 8.53 of the Act. The Company shall make
advance payment of Expenses to Indemnitee no later than thirty (30) days after receipt of the foregoing (and each subsequent request for advancement) by Indemnitee. 

(c) Indemnification Request. In order to obtain indemnification under this Agreement, Indemnitee shall, anytime at Indemnitee’s
discretion following notification by Indemnitee of the commencement of any Proceeding pursuant to Section 9(a) of this Agreement and consistent with the time period for the duration of this Agreement as set forth in Section 14 of this
Agreement, submit to the Company a written request for indemnification pursuant to this Section 9(c), including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to
determine whether and to what extent Indemnitee is entitled to indemnification. No determination of Indemnitee’s entitlement to indemnification shall be made until such written request for a determination is submitted by Indemnitee to the
Company pursuant to this Section 9(c). The failure to submit a written request to the Company will relieve the Company of its indemnification obligations under this Agreement only to the extent the Company can establish that such failure to
make 

  
 6 

 
a written request resulted in actual, material prejudice to it, and the failure to make a written request will not relieve the Company from any liability which it may have to indemnify Indemnitee
otherwise than under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Upon submission of a written request for
indemnification by Indemnitee pursuant to this Section 9(c), Indemnitee’s entitlement to indemnification shall be determined according to Section 10 of this Agreement. 

10. Procedure Upon Application for Indemnification. 

(a) For the avoidance of doubt and notwithstanding anything in this Agreement to the contrary, no indemnification shall be made under this
Agreement without a determination made in accordance with Section 8.55 of the Act that the Indemnitee has met the relevant standard of conduct set forth in Section 8.51 of the Act. Upon receipt of Indemnitee’s written request for
indemnification pursuant to Section 9(c), a determination with respect thereto shall be made in the specific case by one of the following methods: (i) by a majority vote of the Disinterested Directors, even though less than a quorum,
(ii) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum, or (iii) if there are no Disinterested Directors or if the Disinterested Directors so direct, by
Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (iv) by a majority of disinterested shareholders of the Company. Notwithstanding the above, if a determination with respect to
Indemnitee’s right to indemnification is to be made following a Change of Control, such determination shall be made in the specific case by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee.
If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall reasonably cooperate with the person, persons or entity making such
determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected
from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the Disinterested
Directors or Independent Counsel, as the case may be, making such determination shall be advanced and borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company is liable to
indemnify and hold Indemnitee harmless therefrom. 
 (b) In the event the determination of entitlement to indemnification is to be made by
Independent Counsel pursuant to Section 10(a) hereof, the Independent Counsel shall be selected by the Company in accordance with applicable law. The Indemnitee may, within ten (10) days after written notice of such selection, deliver to
the Company a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as
defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as
Independent Counsel unless and until such objection is withdrawn or a Massachusetts Court (as defined in Section 22) has determined that such objection is without merit. If, within twenty (20) days after the later of (i) submission by
Indemnitee of a written request for indemnification pursuant to Section 9(a), and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, Indemnitee may
petition the Massachusetts Courts for 

  
 7 

 
resolution of any objection which shall have been made by Indemnitee to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or
by such other person as the court shall designate. The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(a) hereof. Upon the due commencement of any judicial
proceeding or arbitration pursuant to Section 12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then
prevailing). 
 11. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such
determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a notice and a request for indemnification in accordance with Section 9 of this Agreement. Anyone seeking to overcome
this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by the Board) or of Independent Counsel to have made a determination prior to the
commencement of any judicial proceeding or arbitration pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company
(including by the Board) or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 

(b) If the person, persons or entity empowered or selected under Section 10 of this Agreement to determine whether Indemnitee is
entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of Indemnitee’s written request for indemnification pursuant to Section 9(c) of this Agreement, the requisite
determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary
to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such sixty- (60)-day
period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for
the obtaining or evaluating of documentation and/or information relating thereto. 
 (c) The termination of any Proceeding or of any claim,
issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of
Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal
Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful. 
 (d) Reliance as Safe
Harbor. For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action or failure to act is based on the records or books of account of the Enterprise, including financial
statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal 

  
 8 

 
counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected by the
Enterprise. The provisions of this Section 11(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed or found to have met the applicable standard of conduct set forth in this
Agreement. 
 (e) Actions of Others. The knowledge and/or actions, or failure to act, of any other director, partner, managing
member, officer, agent, employee or trustee of the Enterprise shall not be imputed to Indemnitee for purposes of determining Indemnitee’s right to indemnification under this Agreement. 

12. Remedies of Indemnitee. 

(a) In the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to
indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 or 10(b) of this Agreement, (iii) payment of indemnification is not made pursuant to Section 5 or 7, or the last sentence
of Section 10(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (iv) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within ten
(10) days after a determination has been made that Indemnitee is entitled to indemnification or (v) Indemnitee determines in its sole discretion that such action is appropriate or desirable, Indemnitee shall be entitled to seek an
adjudication by a court of competent jurisdiction as to Indemnitee’s entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at Indemnitee’s option, may seek an award in arbitration to be conducted by a
single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration. 

(b) In the event that a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is not entitled
to indemnification, any judicial proceeding or arbitration, commenced pursuant to this Section 12, shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee shall not be prejudiced by reason of that
adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 12, in the event that the person, persons or entity empowered or selected under Section 10 of this Agreement to determine whether
Indemnitee is entitled to indemnification has not made such a determination within the time period provided for under Section 11(b) of this Agreement, the Company shall stipulate and may not contest that Indemnitee acted in good faith and in a
manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. 

(c) If a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to
make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

(d) To the extent permitted by applicable law, the Company shall be precluded from asserting in any judicial proceeding or arbitration
commenced pursuant to this Section 12 that the 

  
 9 

 
procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the
provisions of this Agreement. 
 (e) The Company shall be liable to indemnify Indemnitee against any and all Expenses and, if requested by
Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefore) advance such Expenses to Indemnitee that are incurred by Indemnitee in connection with any judicial adjudication or arbitration involving
Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is
determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be. Indemnitee shall be required to reimburse all Expenses advanced by the Company under this Section 12 in the event that a final
judicial determination is made that such action brought by Indemnitee was frivolous or not made in good faith. 
 (f) Notwithstanding
anything in this Agreement to the contrary, no determination of entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including nay appeal therein. 

13. Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation. 

(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any
other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s Articles of Organization or Bylaws, or similar organizational documents of any other Enterprise, any agreement, a vote of stockholders or a
resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect to any action taken or omitted by such Indemnitee
in Indemnitee’s Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Massachusetts law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be
afforded currently under the Company’s Articles of Organization or Bylaws, or similar organizational documents of any other Enterprise, and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the
greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, partners, managing
members, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such
director, partner, managing member, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to Section 9(a) hereof, the Company has director and officer liability
insurance in effect, the Company shall give prompt notice of the commencement of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable
action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. 

  
 10 

 (c) The Company hereby acknowledges that Indemnitee has or may have in the future certain
rights to indemnification and/or advancement of expenses provided by other entities and/or organizations (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its
obligations to Indemnitee are primary and any obligation of the Fund Indemnitors, or any insurance carriers providing insurance coverage to or on behalf of any Fund Indemnitor (herein, the “Fund Insurers”), to advance expenses or to
provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses,
judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement (or any other agreement between the Company and Indemnitee), under the Company’s Articles of Organization
or Bylaws, or similar organizational documents of any other Enterprise, without regard to any rights Indemnitee may have against the Fund Indemnitors or any Fund Insurers, and (iii) that it irrevocably waives, relinquishes and releases the Fund
Indemnitors or Fund Insurers from any and all claims against the Fund Indemnitors or Fund Insurers for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the
Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the
extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 13(c). 

(d) Except as provided in paragraph (c) above, in the event of any payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of Indemnitee (other than against the Fund Indemnitors or Fund Insurers), who shall execute all papers required and take all action necessary to secure such rights, including execution of such
documents as are necessary to enable the Company to bring suit to enforce such rights. 
 (e) Except as provided in paragraph
(c) above, the Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and only to the extent that Indemnitee has otherwise actually
received such payment under any insurance policy, contract, agreement or otherwise. 
 (f) Except as provided in paragraph (c) above,
the Company’s obligation hereunder to indemnify, or advance Expenses to, Indemnitee who was, is or will be serving as a director, partner, managing member, officer, employee, agent or trustee of any other Enterprise shall be reduced by any
amount Indemnitee has actually received as indemnification or advancement of Expenses from such other Enterprise. 
 14. Duration of
Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director of the Company or as a director, partner, managing member, officer,
employee, agent or trustee of any other Enterprise; or (b) one (1) year after the final termination (i) of any Proceeding (including any rights of appeal) then pending in respect of which Indemnitee requests indemnification or advancement
of Expenses hereunder and (ii) of any judicial proceeding or arbitration pursuant to Section 12 of this Agreement (including any rights of appeal) involving Indemnitee. This Agreement shall be binding upon the Company and its successors
and assigns and shall inure to the benefit of Indemnitee and Indemnitee’s heirs, executors and administrators. 

  
 11 

 15. Severability. If any provision or provisions of this Agreement shall be held to
be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing
any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by applicable
law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions
of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so
as to give effect to the intent manifested thereby. 
 16. Enforcement. 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in
order to induce Indemnitee to continue to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

(b) This Agreement is intended to supplement the Indemnitee’s rights to indemnification pursuant to the Company’s Articles of
Organization, Bylaws, and/or otherwise, and nothing herein shall be construed to limit, restrict, or eliminate advancement of the Indemnitee’s rights to indemnification pursuant to the Company’s Articles of Organization, Bylaws, and/or
otherwise. 
 (c) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject
hereof and supersedes any and all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof. 

17. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by
the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a wavier of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. 

18. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation,
subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not
relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. 
 19. Notices. All notices,
requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (a) if delivered by hand and receipted for by the party to whom said notice or other communication shall have been
directed, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) if mailed by certified or registered mail with postage
prepaid, on the third business day after the date on which it is so mailed, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification: 

  
 12 

 (a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or
such other address as Indemnitee shall provide in writing to the Company, 
 (b) If to the Company to: TransMedics Group, Inc. 

200 Minuteman Road 

Andover, MA 01810 

Attention: 

E-Mail: 
 or to any other
address as may have been furnished to Indemnitee in writing by the Company. 
 20. Contribution. To the fullest extent permissible
under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for
judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion in order to reflect (i) the
relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officer, employees and agents) and
Indemnitee in connection with such event(s) and/or transaction(s). 
 21. Applicable Law and Consent to Jurisdiction. This Agreement
and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflict of laws rules. Except with respect to any arbitration
commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be
brought only in the state or federal courts located in the Commonwealth of Massachusetts (the “Massachusetts Courts”), and not in any other state or federal court in the United States of America or any court in any other country
(ii) consent to submit to the exclusive jurisdiction of the Massachusetts Courts for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not a resident of the
Commonwealth of Massachusetts, irrevocably Corporation Service Company, 84 State Street, Boston, MA 02109, as its agent in the Commonwealth of Massachusetts as such party’s agent for acceptance of legal process in connection with any such
action or proceeding against such party with the same legal force and validity as if served upon such party personally within the Commonwealth of Massachusetts, (iv) waive any objection to the laying of venue of any such action or proceeding in
the Massachusetts Courts, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Massachusetts Courts has been brought in an improper or inconvenient forum. 

22. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall for all purposes be deemed to be an
original, but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 23. Headings. The headings of the paragraphs of this Agreement are inserted
for convenience 

  
 13 

 
only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 

[Remainder of this page intentionally blank] 

  
 14 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. 
  

					
	TRANSMEDICS GROUP, INC.
		
	By:	 	  

		 	Name:	  	  

		 	Title:	  	  

	
	INDEMNITEE
	
	  

	Name:	 	  

		
	Address:	 	
	  

	  

	  

	  

		
	E-mail:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]